{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:32:30Z","timestamp":1725280350007},"reference-count":119,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Mineralocorticoid receptor antagonists are a second-line class of antihypertensive drugs,\nwhich have been accounted for as the optimal add-on therapy in the triple algorithm for the management of resistant\nhypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>To assess the effects of mineralocorticoid receptor antagonists in the treatment of patients with essential\nhypertension and resistant hypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>We conducted a meticulous review of the literature and comprehensive identification of the clinical\ntrials assessing the efficacy of mineralocorticoid receptor antagonists in individuals with primary and resistant\nhypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>MRAs have been thoroughly tested in several clinical studies in relevance to blood pressure lowering\neffects, over the last six decades. Accumulating data observed that MRAs resulted in a significant reduction in\nblood pressure level in patients with resistant hypertension. In addition, spironolactone was found to beneficially\naffect the management of resistant hypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Mineralocorticoid receptor antagonists exert a significant antihypertensive effect. Future welldesigned\nrandomized controlled studies are greatly needed to address crucial clinical aspects in the field.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190306163310","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T11:33:12Z","timestamp":1552044792000},"page":"5500-5507","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension"],"prefix":"10.2174","volume":"24","author":[{"given":"Konstantinos P.","family":"Imprialos","sequence":"first","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Bouloukou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kerpiniotis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Katsimardou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Bakogiannis","sequence":"additional","affiliation":[{"name":"Third Department of Cardiology, Hippokration Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, George Washington University, Washington, DC 20422, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"","year":"2017","unstructured":". Lancet,  NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19\u00b71 million participants., 2017, 389, 37-55,","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"Chow C.K.","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S. JAMA, Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries., 2013, 310, 959-968,","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"Lewington S.","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Lancet, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies., 2002, 360, 1903-1913,","journal-title":"Lancet"},{"key":"ref=4","first-page":"235","volume":"3","author":"Lip G.Y.H.","year":"2017","unstructured":"Lip GYH, Coca A, Kahan T. Eur Heart J Cardiovasc Pharmacother, Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE)., 2017, 3, 235-250,","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e328342c659","volume":"29","author":"Viigimaa M.","year":"2011","unstructured":"Viigimaa M, Doumas M, Vlachopoulos C. J Hypertens, Hypertension and sexual dysfunction: time to act., 2011, 29, 403-407,","journal-title":"J Hypertens"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1570161115666170609101502","volume":"16","author":"Imprialos K.P.","year":"2018","unstructured":"Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Curr Vasc Pharmacol, Sexual dysfunction, cardiovascular risk and effects of pharmacotherapy., 2018, 16, 130-142,","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamaneurol.2017.1658","volume":"74","author":"Gottesman R.F.","year":"2017","unstructured":"Gottesman RF, Albert MS, Alonso A. JAMA Neurol, Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort., 2017, 74, 1246-1254,","journal-title":"JAMA Neurol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/HYPERTENSIONAHA.112.201400","volume":"60","author":"Vishram J.K.","year":"2012","unstructured":"Vishram JK, Borglykke A, Andreasen AH. Hypertension, Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project., 2012, 60, 1117-1123,","journal-title":"Hypertension"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjhyper.2006.08.004","volume":"20","author":"Brown D.W.","year":"2007","unstructured":"Brown DW, Giles WH, Greenlund KJ. Am J Hypertens, Blood pressure parameters and risk of fatal stroke, NHANES II mortality study., 2007, 20, 338-341,","journal-title":"Am J Hypertens"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.jacc.2017.02.060","volume":"69","author":"Rovio S.P.","year":"2017","unstructured":"Rovio SP, Pahkala K, Nevalainen J. J Am Coll Cardiol, Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study., 2017, 69, 2279-2289,","journal-title":"J Am Coll Cardiol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00004872-200304000-00013","volume":"21","author":"Lawes C.M.","year":"2003","unstructured":"Lawes CM, Rodgers A, Bennett DA. J Hypertens, Blood pressure and cardiovascular disease in the Asia Pacific region., 2003, 21, 707-716,","journal-title":"J Hypertens"},{"key":"ref=12","first-page":"e13","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS. Hypertension, 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines., 2018, 71, e13-e115,","journal-title":"Hypertension"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams B.","year":"2018","unstructured":"Williams B, Mancia G, Spiering W. J Hypertens, 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension., 2018, 36, 1953-2041,","journal-title":"J Hypertens"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"Forouzanfar M.H.","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA. JAMA, Global burden of hypertension and systolic blood pressure of at least 110 to 115mmHg, 1990-2015., 2017, 317, 165-182,","journal-title":"JAMA"},{"key":"ref=15","first-page":"217","author":"Papademetriou V.","year":"2016","unstructured":"Papademetriou V, Doumas M. ., , 2016, , Selecting optimum antihypertensive therapy.","journal-title":"Selecting optimum antihypertensive therapy"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/HJH.0000000000001547","volume":"35","author":"Thomopoulos C.","year":"2017","unstructured":"Thomopoulos C, Parati G, Zanchetti A. J Hypertens, Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials., 2017, 35, 2150-2160,","journal-title":"J Hypertens"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"Ettehad D.","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A. Lancet, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis., 2016, 387, 957-967,","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD. Eur J Heart Fail, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., 2016, 18, 891-975,","journal-title":"Eur J Heart Fail"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt B.","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ. N Engl J Med, The effect of spironolactone on morbidity and mortality in patients with severe heart failure., 1999, 341, 709-717,","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel drugs for hypertension and heart failure: struggling for a place under the sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjmed.2018.09.011","volume":"132","author":"Bayoumi E.","year":"2019","unstructured":"Bayoumi E, Lam PH, Dooley DJ. Am J Med, Spironolactone and outcomes in older patients with heart failure and reduced ejection fraction., 2019, 132, 71-80,","journal-title":"Am J Med"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"Zannad F.","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H. N Engl J Med, Eplerenone in patients with systolic heart failure and mild symptoms., 2011, 364, 11-21,","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"Ando K.","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. Lancet Diabetes Endocrinol, Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial., 2014, 2, 944-953,","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"Pitt B.","year":"2003","unstructured":"Pitt B, Remme W, Zannad F. N Engl J Med, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction., 2003, 348, 1309-1321,","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/ijms18051032","volume":"18","author":"Funder J.W.","year":"2017","unstructured":"Funder JW. Int J Mol Sci, Aldosterone and mineralocorticoid receptors-physiology and pathophysiology., 2017, 18, 1032-,","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1210\/en.2010-1444","volume":"152","author":"Kassahn K.S.","year":"2011","unstructured":"Kassahn KS, Ragan MA, Funder JW. Endocrinology, Mineralocorticoid receptors: evolutionary and pathophysiological considerations., 2011, 152, 1883-1890,","journal-title":"Endocrinology"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cen.12705","volume":"83","author":"Ahmed A.H.","year":"2015","unstructured":"Ahmed AH, Gordon RD, Ward G, Wolley M, Kogovsek C, Stowasser M. Clin Endocrinol (Oxf), Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase? Results of a preliminary study., 2015, 83, 303-307,","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1633591100","volume":"100","author":"Fjeld C.C.","year":"2003","unstructured":"Fjeld CC, Birdsong WT, Goodman RH. Proc Natl Acad Sci USA, Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor., 2003, 100, 9202-9207,","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/09513590.2018.1480713","volume":"34","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K, Sotiriadis A, Patoulias D. Gynecol Endocrinol, Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome., 2018, 34, 1019-1021,","journal-title":"Gynecol Endocrinol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","volume":"31","author":"Buonafine M.","year":"2018","unstructured":"Buonafine M, Bonnard B, Jaisser F. Am J Hypertens, Mineralocorticoid receptor and cardiovascular disease., 2018, 31, 1165-1174,","journal-title":"Am J Hypertens"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","volume":"66","author":"Hollenberg N.K.","year":"2004","unstructured":"Hollenberg NK. Kidney Int, Aldosterone in the development and progression of renal injury., 2004, 66, 1-9,","journal-title":"Kidney Int"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","volume":"116","author":"Oparil S.","year":"2015","unstructured":"Oparil S, Schmieder RE. Circ Res, New approaches in the treatment of hypertension., 2015, 116, 1074-1095,","journal-title":"Circ Res"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","volume":"68","author":"Jaisser F.","year":"2016","unstructured":"Jaisser F, Farman N. Pharmacol Rev, Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology., 2016, 68, 49-75,","journal-title":"Pharmacol Rev"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G\u00fcder G.","year":"2007","unstructured":"G\u00fcder G, Bauersachs J, Frantz S. Circulation, Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure., 2007, 115, 1754-1761,","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","volume":"1","author":"Cranston W.I.","year":"1962","unstructured":"Cranston WI, Juel-Jensen BE. Lancet, The effects of spironolactone and chlorthalidone on arterial pressure., 1962, 1, 1161-1164,","journal-title":"Lancet"},{"key":"ref=36","author":"","year":"","unstructured":"The effects of spironolactone and chlorthalidone on arterial pressure. https:\/\/www.fda.gov\/downloads\/Drugs\/...\/ Guidances\/ucm075072.pdf, ,"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1966.03110240051022","volume":"198","author":"Wolf R.L.","year":"1966","unstructured":"Wolf RL, Mendlowitz M, Roboz J, Styan GP, Kornfeld P, Weigl A. JAMA, Treatment of hypertension with spironolactone. Double-blind study., 1966, 198, 1143-1149,","journal-title":"JAMA"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.1968.03140220023006","volume":"204","author":"Winer B.M.","year":"1968","unstructured":"Winer BM, Lubbe WF, Colton T. JAMA, Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together., 1968, 204, 775-779,","journal-title":"JAMA"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0140-6736(73)92869-9","volume":"2","author":"George C.F.","year":"1973","unstructured":"George CF, Breckenridge AM, Dollery CT. Lancet, Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia., 1973, 2, 1288-1291,","journal-title":"Lancet"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.HYP.2.5.672","volume":"2","author":"Scherst\u00e9n B.","year":"1980","unstructured":"Scherst\u00e9n B, Thulin T, Kuylenstierna J. Hypertension, Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study., 1980, 2, 672-679,","journal-title":"Hypertension"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/0002-9149(75)90174-5","volume":"36","author":"Drayer J.I.","year":"1975","unstructured":"Drayer JI, Kloppenborg PW, Festen J, van\u2019t Laar A, Benraad TJ. Am J Cardiol, Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension., 1975, 36, 716-721,","journal-title":"Am J Cardiol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2125.1981.tb01271.x","volume":"12","author":"Bell G.M.","year":"1981","unstructured":"Bell GM, Fananapazir L, Anderton JL. Br J Clin Pharmacol, Comparison of single and divided daily dose spironolactone in the control of hypertension., 1981, 12, 585-588,","journal-title":"Br J Clin Pharmacol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jama.1974.03230180016005","volume":"227","author":"Douglas J.G.","year":"1974","unstructured":"Douglas JG, Hollifield JW, Liddle GW. JAMA, Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination., 1974, 227, 518-521,","journal-title":"JAMA"},{"key":"ref=44","first-page":"31","volume":"128","author":"Kreeft J.H.","year":"1983","unstructured":"Kreeft JH, Larochelle P, Ogilvie RI. Can Med Assoc J, Comparison of chlorthalidone and spironolactone in low--renin essential hypertension., 1983, 128, 31-34,","journal-title":"Can Med Assoc J"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","volume":"116","author":"Hood S.J.","year":"2007","unstructured":"Hood SJ, Taylor KP, Ashby MJ, Brown MJ. Circulation, The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio., 2007, 116, 268-275,","journal-title":"Circulation"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"Mottram P.M.","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Circulation, Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure., 2004, 110, 558-565,","journal-title":"Circulation"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1751-7176.2010.00339.x","volume":"12","author":"Costa M.B.","year":"2010","unstructured":"Costa MB, Andrade Ezequiel DG, Morais Lovis JC, Oliveira MM, Baumgratz de Paula R. J Clin Hypertens (Greenwich), Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome., 2010, 12, 753-755,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5414\/CNP72449","volume":"72","author":"Bomback A.S.","year":"2009","unstructured":"Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M. Clin Nephrol, Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage., 2009, 72, 449-456,","journal-title":"Clin Nephrol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"Mehdi U.F.","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. J Am Soc Nephrol, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy., 2009, 20, 2641-2650,","journal-title":"J Am Soc Nephrol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","volume":"40","author":"Grandi A.M.","year":"2002","unstructured":"Grandi AM, Imperiale D, Santillo R. Hypertension, Aldosterone antagonist improves diastolic function in essential hypertension., 2002, 40, 647-652,","journal-title":"Hypertension"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","volume":"11","author":"Ubaid-Girioli S.","year":"2009","unstructured":"Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC. J Clin Hypertens (Greenwich), Aldosterone excess or escape: Treating resistant hypertension., 2009, 11, 245-252,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","volume":"60","author":"Raheja P.","year":"2012","unstructured":"Raheja P, Price A, Wang Z. Hypertension, Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients., 2012, 60, 319-325,","journal-title":"Hypertension"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"Garthwaite S.M.","year":"2004","unstructured":"Garthwaite SM, McMahon EG. Mol Cell Endocrinol, The evolution of aldosterone antagonists., 2004, 217, 27-31,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"Colussi G.","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. J Hypertens, Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension., 2013, 31, 3-15,","journal-title":"J Hypertens"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"Kolkhof P.","year":"2012","unstructured":"Kolkhof P, Borden SA. Mol Cell Endocrinol, Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics., 2012, 350, 310-317,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"Kolkhof P.","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Curr Opin Nephrol Hypertens, Nonsteroidal antagonists of the mineralocorticoid receptor., 2015, 24, 417-424,","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.nephro.2017.02.003","volume":"13","author":"Ruilope L.M.","year":"2017","unstructured":"Ruilope LM, Tamargo J. Nephrol Ther, Renin-angiotensin system blockade: Finerenone., 2017, 13, S47-S53,","journal-title":"Nephrol Ther"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehv550","volume":"37","author":"Mulder P.","year":"2016","unstructured":"Mulder P. Eur Heart J, Finerenone improves diastolic function in a preclinical model of type 2 diabetes mellitus., 2016, 37, 829-,","journal-title":"Eur Heart J"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"Lentini S.","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Fundam Clin Pharmacol, Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies., 2016, 30, 172-184,","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"Heinig R.","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Clin Pharmacol Drug Dev, Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment., 2016, 5, 488-501,","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"Pitt B.","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P. Eur Heart J, Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial., 2013, 34, 2453-2463,","journal-title":"Eur Heart J"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"Filippatos G.","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M. Eur Heart J, A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease., 2016, 37, 2105-2114,","journal-title":"Eur Heart J"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial., 2015, 314, 884-894,","journal-title":"JAMA"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"Roush G.C.","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB. J Hypertens, Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses., 2016, 34, 11-19,","journal-title":"J Hypertens"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1161\/CIRCULATIONAHA.117.030848","volume":"137","author":"Beddhu S.","year":"2018","unstructured":"Beddhu S, Chertow GM, Cheung AK. Circulation, Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control., 2018, 137, 134-143,","journal-title":"Circulation"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jacc.2014.04.065","volume":"64","author":"Sim J.J.","year":"2014","unstructured":"Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. J Am Coll Cardiol, Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population., 2014, 64, 588-597,","journal-title":"J Am Coll Cardiol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","volume":"388","author":"Vidal-Petiot E.","year":"2016","unstructured":"Vidal-Petiot E, Ford I, Greenlaw N. Lancet, Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study., 2016, 388, 2142-2152,","journal-title":"Lancet"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","volume":"31","author":"Bangalore S.","year":"2010","unstructured":"Bangalore S, Messerli FH, Wun CC. Eur Heart J, J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial., 2010, 31, 2897-2908,","journal-title":"Eur Heart J"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1161\/CIRCULATIONAHA.117.032605","volume":"137","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K, Imprialos KP, Grassos C. Circulation, Letter by Stavropoulos et al. Regarding Article, \u201cInfluence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control., 2018, 137, 2664-2665,","journal-title":"Circulation"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10741-018-9689-9","volume":"23","author":"Bazoukis G.","year":"2018","unstructured":"Bazoukis G, Thomopoulos C, Tse G, Tsioufis C. Heart Fail Rev, Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis., 2018, 23, 547-553,","journal-title":"Heart Fail Rev"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","volume":"177","author":"Pelliccia F.","year":"2014","unstructured":"Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Int J Cardiol, Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis., 2014, 177, 219-228,","journal-title":"Int J Cardiol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/HJH.0000000000001671","volume":"36","author":"Bazoukis G.","year":"2018","unstructured":"Bazoukis G, Thomopoulos C, Tsioufis C. J Hypertens, Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension., 2018, 36, 987-994,","journal-title":"J Hypertens"},{"key":"ref=73","first-page":"CD008169","author":"Batterink J.","year":"2010","unstructured":"Batterink J, Stabler SN, Tejani AM, Fowkes CT. Cochrane Database Syst Rev, Spironolactone for hypertension., 2010, 36, CD008169-,","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=74","first-page":"CD008996","volume":"2","author":"Tam T.S.","year":"2017","unstructured":"Tam TS, Wu MH, Masson SC. Cochrane Database Syst Rev, Eplerenone for hypertension., 2017, 2, CD008996-,","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","volume":"124","author":"Egan B.M.","year":"2011","unstructured":"Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Circulation, Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008., 2011, 124, 1046-1058,","journal-title":"Circulation"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.08929","volume":"70","author":"Cai A.","year":"2017","unstructured":"Cai A, Calhoun DA. Hypertension, Resistant hypertension: an update of experimental and clinical findings., 2017, 70, 5-9,","journal-title":"Hypertension"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrneph.2012.260","volume":"9","author":"Sarafidis P.A.","year":"2013","unstructured":"Sarafidis PA, Georgianos P, Bakris GL. Nat Rev Nephrol, Resistant hypertension--its identification and epidemiology., 2013, 9, 51-58,","journal-title":"Nat Rev Nephrol"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/jch.13144","volume":"20","author":"Brandani L.","year":"2018","unstructured":"Brandani L. J Clin Hypertens (Greenwich), Resistant hypertension: a therapeutic challenge., 2018, 20, 76-78,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jch.12886","volume":"18","author":"Sarganas G.","year":"2016","unstructured":"Sarganas G, Neuhauser HK. J Clin Hypertens (Greenwich), Untreated, uncontrolled, and apparent resistant hypertension: results of the German Health Examination survey 2008-2011., 2016, 18, 1146-1154,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jch.12617","volume":"18","author":"Turner J.R.","year":"2016","unstructured":"Turner JR, Lee J. J Clin Hypertens (Greenwich), American Society of Hypertension Scientific Statements Addressing Resistant Hypertension., 2016, 18, 175-178,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.2174\/1381612811319130008","volume":"19","author":"Bruno R.M.","year":"2013","unstructured":"Bruno RM, Di Giulio A, Bernini G. Curr Pharm Des, Device-based therapies for resistant hypertension., 2013, 19, 2401-2408,","journal-title":"Curr Pharm Des"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/ccd.26028","volume":"86","author":"Weber M.A.","year":"2015","unstructured":"Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Catheter Cardiovasc Interv, Renal denervation for the treatment of hypertension: Making a new start, getting it right., 2015, 86, 855-863,","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref=83","first-page":"964394","volume":"2011","author":"Papademetriou V.","year":"2011","unstructured":"Papademetriou V, Doumas M, Faselis C. Int J Hypertens, Carotid baroreceptor stimulation for the treatment of resistant hypertension., 2011, 2011, 964394-,","journal-title":"Int J Hypertens"},{"key":"ref=84","first-page":"66","volume":"16","author":"Tsioufis C.","year":"2017","unstructured":"Tsioufis C, Dimitriadis K, Kordalis A. Curr Vasc Pharmacol, Renal denervation therapy: can it contribute to better blood pressure control in hypertension?, 2017, 16, 66-69,","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=85","author":"Manolis AJ","year":"2015","unstructured":"Manolis AJ, Kallistratos MS, Doumas M. ,  Recent advances in the management of resistant hypertension. F1000Prime Rep, 7: 03, 2015"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jch.12988","volume":"19","author":"Chen S.","year":"2017","unstructured":"Chen S, Kiuchi MG, Acou WJ. J Clin Hypertens (Greenwich), Feasibility of catheter ablation renal denervation in \u201cmild\u201d resistant hypertension., 2017, 19, 361-368,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1570161115666170426145612","volume":"16","author":"Doumas M.","year":"2017","unstructured":"Doumas M, Boutari C, Tsioufis C, Dimitriadis K, Triantafyllou A, Douma S. Curr Vasc Pharmacol, Clinical value of measuring the renin\/aldosterone levels: optimizing the management of uncontrolled\/resistant hypertension., 2017, 16, 10-14,","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jch.12617","volume":"18","author":"Turner J.R.","year":"2016","unstructured":"Turner JR, Lee J. J Clin Hypertens (Greenwich), American Society of Hypertension Scientific Statements Addressing Resistant Hypertension., 2016, 18, 175-178,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"Krum H.","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R. Lancet, Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study., 2009, 373, 1275-1281,","journal-title":"Lancet"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"Esler M.D.","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Lancet, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial., 2010, 376, 1903-1909,","journal-title":"Lancet"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.113.005405","volume":"129","author":"Papademetriou V.","year":"2014","unstructured":"Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Circulation, Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions., 2014, 129, 1440-1451,","journal-title":"Circulation"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1161\/HYPERTENSIONAHA.111.178145","volume":"58","author":"Petidis K.","year":"2011","unstructured":"Petidis K, Anyfanti P, Doumas M. Hypertension, Renal sympathetic denervation: renal function concerns., 2011, 58, e19-,","journal-title":"Hypertension"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCRESAHA.115.304099","volume":"115","author":"Papademetriou V.","year":"2014","unstructured":"Papademetriou V, Tsioufis C, Doumas M. Circ Res, Renal denervation and Symplicity HTN-3: \u201cDubium sapientiae initium\u201d (doubt is the beginning of wisdom)., 2014, 115, 211-214,","journal-title":"Circ Res"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11936-017-0536-4","volume":"19","author":"Raman V.K.","year":"2017","unstructured":"Raman VK, Tsioufis C, Doumas M, Papademetriou V. Curr Treat Options Cardiovasc Med, Renal denervation therapy for drug resistant hypertension: does it still work?, 2017, 19, 39-,","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"ref=95","first-page":"66","volume":"16","author":"Tsioufis C.","year":"2017","unstructured":"Tsioufis C, Dimitriadis K, Kordalis A. Curr Vasc Pharmacol, Renal denervation therapy: can it contribute to better blood pressure control in hypertension?, 2017, 16, 66-69,","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jch.12590","volume":"17","author":"Weber M.A.","year":"2015","unstructured":"Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. J Clin Hypertens (Greenwich), Renal denervation for the treatment of hypertension: making a new start, getting it right., 2015, 17, 743-750,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jch.13069","volume":"19","author":"Afsar B.","year":"2017","unstructured":"Afsar B, Sag AA, Kanbay M. J Clin Hypertens (Greenwich), Should we take renal denervation with a grain of salt?, 2017, 19, 1134-1136,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jch.12324","volume":"16","author":"Doumas M.","year":"2014","unstructured":"Doumas M, Lazaridis A, Papademetriou V. J Clin Hypertens (Greenwich), Renal nerve ablation for resistant hypertension: the dust has not yet settled., 2014, 16, 399-400,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jch.13261","volume":"20","author":"Doumas M.","year":"2018","unstructured":"Doumas M, Stavropoulos K, Imprialos KP, Athyros VG, Karagiannis A. J Clin Hypertens (Greenwich), Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?, 2018, 20, 634-636,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1001\/jama.2014.5180","volume":"311","author":"Vongpatanasin W.","year":"2014","unstructured":"Vongpatanasin W. JAMA, Resistant hypertension: a review of diagnosis and management., 2014, 311, 2216-2224,","journal-title":"JAMA"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(09)60624-3","volume":"373","author":"Doumas M.","year":"2009","unstructured":"Doumas M, Douma S. Lancet, Interventional management of resistant hypertension., 2009, 373, 1228-1230,","journal-title":"Lancet"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"Townsend R.R.","year":"2017","unstructured":"Townsend RR, Mahfoud F, Kandzari DE. Lancet, Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial., 2017, 390, 2160-2170,","journal-title":"Lancet"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jch.13252","volume":"20","author":"Denegri A.","year":"2018","unstructured":"Denegri A, Naduvathumuriyil T, L\u00fcscher TF, Sudano I. J Clin Hypertens (Greenwich), Renal nerve ablation reduces blood pressure in resistant hypertension: Long-term clinical outcomes in a single-center experience., 2018, 20, 627-633,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"Kandzari D.E.","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F. Lancet, Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial., 2018, 391, 2346-2355,","journal-title":"Lancet"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/S0140-6736(17)32337-1","volume":"390","author":"Spiering W.","year":"2017","unstructured":"Spiering W, Williams B, Van der Heyden J. Lancet, Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study., 2017, 390, 2655-2661,","journal-title":"Lancet"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/fca.15.9","volume":"11","author":"Donazzan L.","year":"2015","unstructured":"Donazzan L, Ewen S, Papademetriou V. Future Cardiol, Drug therapy for the patient with resistant hypertension., 2015, 11, 191-202,","journal-title":"Future Cardiol"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jch.12860","volume":"18","author":"Eguchi K.","year":"2016","unstructured":"Eguchi K, Kabutoya T, Hoshide S, Ishikawa S, Kario K. J Clin Hypertens (Greenwich), Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension., 2016, 18, 1250-1257,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"Williams B.","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S. Lancet, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial., 2015, 386, 2059-2068,","journal-title":"Lancet"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"Krieger E.M.","year":"2018","unstructured":"Krieger EM, Drager LF, Giorgi DMA. Hypertension, Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment)., 2018, 71, 681-690,","journal-title":"Hypertension"},{"key":"ref=110","first-page":"7270","volume":"8","author":"Guo H.","year":"2015","unstructured":"Guo H, Xiao Q. Int J Clin Exp Med, Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials., 2015, 8, 7270-7278,","journal-title":"Int J Clin Exp Med"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"Wang C.","year":"2016","unstructured":"Wang C, Xiong B, Huang J. Heart Lung Circ, Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials., 2016, 25, 1021-1030,","journal-title":"Heart Lung Circ"},{"key":"ref=112","author":"Zhao D","year":"2017","unstructured":"Zhao D, Liu H, Dong P. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension., , 233:113-7., 2017","journal-title":"A meta-analysis of add-on use of spironolactone in patients with resistant hypertension"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","volume":"39","author":"Liu L.","year":"2017","unstructured":"Liu L, Xu B, Ju Y. Clin Exp Hypertens, Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials., 2017, 39, 257-263,","journal-title":"Clin Exp Hypertens"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/HJH.0000000000001025","volume":"34","author":"Oliveras A.","year":"2016","unstructured":"Oliveras A, Armario P, Clar\u00e0 A. J Hypertens, Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial., 2016, 34, 1863-1871,","journal-title":"J Hypertens"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ajh\/hpw085","volume":"30","author":"de la Sierra A.","year":"2017","unstructured":"de la Sierra A, Pareja J, Armario P. Am J Hypertens, Renal denervation vs. spironolactone in resistant hypertension: Effects on circadian patterns and blood pressure variability., 2017, 30, 37-41,","journal-title":"Am J Hypertens"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/HYPERTENSIONAHA.114.04019","volume":"65","author":"Rosa J.","year":"2015","unstructured":"Rosa J, Widimsk\u00fd P, Tou\u0161ek P. Hypertension, Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study., 2015, 65, 407-413,","journal-title":"Hypertension"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","volume":"67","author":"Rosa J.","year":"2016","unstructured":"Rosa J, Widimsk\u00fd P, Waldauf P. Hypertension, Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study., 2016, 67, 397-403,","journal-title":"Hypertension"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/HJH.0000000000001257","volume":"35","author":"Rosa J.","year":"2017","unstructured":"Rosa J, Widimsk\u00fd P, Waldauf P. J Hypertens, Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study., 2017, 35, 1093-1099,","journal-title":"J Hypertens"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jch.13146","volume":"20","author":"Stavropoulos K.","year":"2018","unstructured":"Stavropoulos K, Imprialos KP, Doumas M. J Clin Hypertens (Greenwich), Sacubitril\/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension., 2018, 20, 65-68,","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T21:41:57Z","timestamp":1558820517000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170509\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":119,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190306163310","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}